Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volasertib plus low-dose cytarabine versus placebo plus low-dose cytarabine in older untreated AML patients ineligible for intensive induction
NL-OMON41320Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Volasertib + low-dose cytarabine with Placebo + low-dose cytarabine (2 arms). Primary endpoint: Complete remission and complete remission with incomplete blood count recovery. Started Aug 2013; status: active, not recruiting.
02
Drugs
volasertibcytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON41320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41320.